A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures

被引:1
|
作者
Das, Agneesh Pratim [1 ,2 ]
Nandekar, Prajwal [3 ]
Mathur, Puniti [2 ]
Agarwal, Subhash M. [1 ,4 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, Noida, Uttar Pradesh, India
[2] Amity Univ Uttar Pradesh, Amity Inst Biotechnol, Noida, Uttar Pradesh, India
[3] Schrodinger India Pvt Ltd, Bengaluru, Karnataka, India
[4] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, I-7,Sect 39, Noida 201301, Uttar Pradesh, India
关键词
binding pose metadynamics; cross docking; drug discovery; EGFR; kinase; structure selection; virtual screening; NONCOVALENT INHIBITORS; RECEPTOR; DOCKING; RESISTANCE; BINDING;
D O I
10.1002/pro.4740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening (VS) is a routine method to evaluate chemical libraries for lead identification. Therefore, the selection of appropriate protein structures for VS is an essential prerequisite to identify true actives during docking. But the presence of several crystal structures of the same protein makes it difficult to select one or few structures rationally for screening. Therefore, a computational prioritization protocol has been developed for shortlisting crystal structures that identify true active molecules with better efficiency. As identification of small-molecule inhibitors is an important clinical requirement for the T790M/L858R (TMLR) EGFR mutant, it has been selected as a case study. The approach involves cross-docking of 21 co-crystal ligands with all the structures of the same protein to select structures that dock non-native ligands with lower RMSD. The cross docking performance was then correlated with ligand similarity and binding-site conformational similarity. Eventually, structures were shortlisted by integrating cross-docking performance, and ligand and binding-site similarity. Thereafter, binding pose metadynamics was employed to identify structures having stable co-crystal ligands in their respective binding pockets. Finally, different enrichment metrics like BEDROC, RIE, AUAC, and EF1% were evaluated leading to the identification of five TMLR structures (5HCX, 5CAN, 5CAP, 5CAS, and 5CAO). These structures docked a number of non-native ligands with low RMSD, contain structurally dissimilar ligands, have conformationally dissimilar binding sites, harbor stable co-crystal ligands, and also identify true actives early. The present approach can be implemented for shortlisting protein targets of any other important therapeutic kinases.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway
    Sun, Peiyuan
    Zhang, Shuanggou
    Qu, Yana
    Li, Xuanyou
    Chen, Guirui
    Wang, Xuanjun
    Sheng, Jun
    Wang, Jing
    BIOORGANIC CHEMISTRY, 2025, 154
  • [42] Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment
    Wang, Cheng
    Wang, Xin
    Huang, Zhi
    Wang, Tianqi
    Nie, Yongwei
    Yang, Shengyong
    Xiang, Rong
    Fan, Yan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 237
  • [43] Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
    Fawwaz, Muammar
    Mishiro, Kenji
    Nishii, Ryuichi
    Sawazaki, Izumi
    Shiba, Kazuhiro
    Kinuya, Seigo
    Ogawa, Kazuma
    MOLECULES, 2020, 25 (12):
  • [44] Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
    Suriya, Utid
    Mahalapbutr, Panupong
    Wimonsong, Watchara
    Yotphan, Sirilata
    Choowongkomon, Kiattawee
    Rungrotmongkol, Thanyada
    MOLECULES, 2022, 27 (24):
  • [45] Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
    Kanbour, Aladdin
    Salih, Faroug
    Abualainin, Wafa
    Abdelrazek, Mohamed
    Szabados, Lajos
    Al-Bozom, Issam
    Omar, Nabil E.
    ONCOTARGETS AND THERAPY, 2022, 15 : 659 - 667
  • [46] Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC)
    Pawara, Rahul
    Ahmad, Iqrar
    Nayak, Deepika
    Wagh, Shivani
    Wadkar, Avinash
    Ansari, Azim
    Belamkar, Sateesh
    Surana, Sanjay
    Kundu, Chanakya Nath
    Patil, Chandragauda
    Patel, Harun
    BIOORGANIC CHEMISTRY, 2021, 115
  • [47] Synthesis and structure-activity-relationship of 3,4-Diaryl-1H-pyrrolo[2,3-b]pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M
    Guenther, Marcel
    Laux, Julian
    Laufer, Stefan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 : 91 - 96
  • [48] A Patient With Metastatic Lung Adenocarcinoma Harboring Concurrent EGFR L858R, EGFR Germline T790M, and PIK3CA Mutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer
    Lammers, Philip E.
    Lovly, Christine M.
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (01): : 6 - 11
  • [49] Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)
    Karnik, Kshipra S.
    Sarkate, Aniket P.
    Tiwari, Shailee V.
    Azad, Rajaram
    Burra, Prasad V. L. S.
    Wakte, Pravin S.
    BIOORGANIC CHEMISTRY, 2021, 107
  • [50] Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)
    Karnik, Kshipra S.
    Sarkate, Aniket P.
    Tiwari, Shailee V.
    Azad, Rajaram
    Wakte, Pravin S.
    BIOORGANIC CHEMISTRY, 2021, 115